{
  "Country": "EN",
  "PICOs": [
    {
      "Population": "Adults with previously treated KRAS G12C mutation-positive locally advanced or metastatic NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Overall survival, progression-free survival, health-related quality of life"
    },
    {
      "Population": "Adults with previously treated KRAS G12C mutation-positive locally advanced or metastatic NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel plus Nintedanib",
      "Outcomes": "Overall survival, progression-free survival, health-related quality of life"
    },
    {
      "Population": "Adults with advanced NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Overall survival, progression-free survival utilities"
    },
    {
      "Population": "Adults with advanced NSCLC",
      "Intervention": "New medicine under assessment",
      "Comparator": "Erlotinib with Docetaxel",
      "Outcomes": "Utilities in progression-free health state"
    }
  ]
}